SynthesisPloS one2016
High Serum Tumor Necrosis Factor-Alpha Levels in Women with Polycystic Ovary Syndrome: A Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Circulating cytokines levels and the risk of polycystic ovary syndrome: A Mendelian randomization analysis.Medicine · 2025Pooled it
- Pooled it
- Pooled it
- The effect of Curcumin on metabolic parameters and androgen level in women with polycystic ovary syndrome: a randomized controlled trial.BMC endocrine disorders · 2023Trial
- The immunogenetic basis of ovarian apoptosis: from TNF-α polymorphisms and signaling pathways to glucocorticoid-mediated rescue.Journal of ovarian research · 2026Review
- The effects ofResearch in pharmaceutical sciences · 2026Article
- Date palm pollen extract improves fertility and pregnancy outcomes in letrozole-induced polycystic ovary syndrome rats.Journal of molecular histology · 2026Article
- Integrative Mendelian Randomization and Whole-Blood Transcriptomic Analysis Implicate a Myeloid-Inflammation Axis in Polycystic Ovary Syndrome.International journal of women's health · 2026Article
- Exosomes for Polycystic Ovary Syndrome Treatment: Mechanisms and Therapeutic Potential.International journal of nanomedicine · 2026Review
- Review
- Proinflammatory markers in women with type 1 diabetes and polycystic ovary syndrome.Scientific reports · 2025Article
- The application of procyanidins in diabetes and its complications: a review of preclinical studies.Frontiers in pharmacology · 2025Review
- Article
- The Inflammatory State of Follicular Fluid Combined with Negative Emotion Indicators can Predict Pregnancy Outcomes in Patients with PCOS.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Review
- Effects of AIDiet intervention to improve diet quality, immuno-metabolic health in normal and overweight PCOS girls: a pilot study.Scientific reports · 2024Article
- Rethinking the application of nanoparticles in women's reproductive health and assisted reproduction.Nanomedicine (London, England) · 2024Review
- Comparative Evaluation of Adipokine Metrics for the Diagnosis of Gestational Diabetes Mellitus.International journal of molecular sciences · 2023Article
- Biomarkers in Polycystic Ovary Syndrome.Current opinion in physiology · 2023Article
- Potentials of curcumin against polycystic ovary syndrome: Pharmacological insights and therapeutic promises.Heliyon · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study is to assess the TNF-α levels in PCOS patients and healthy controls. A comprehensive electronic search in Medline, Embase, and the Cochrane Library database was conducted up to July 2016. Random-effects model was used to estimate the standardized mean differences (SMDs) with 95% confidence intervals (CIs). Twenty-nine studies with a total of 1960 participants (1046 PCOS patients and 914 controls) were included in this meta-analysis. The TNF-α levels in PCOS patients were significantly higher than those in controls (random-effects, SMD = 0.60, 95% CI = 0.28-0.92, P<0.001). With regard to the subgroup analyses stratified by ethnicity, study quality, methods, and BMI, significantly high TNF-α levels were found in patients with PCOS in almost all of these subgroups. In the subgroup stratified by HOMA-IR ratio and T ratio, significant differences were only observed in the subgroups with HOMA-IR ratio of >1.72(SMD = 0.967, 95% CI = 0.103-1.831, P = 0.028, I2 = 93.5%) and T ratio>2.10 (SMD = 1.420, 95% CI = 0.429-2.411, P = 0.005, I2 = 96.1%). By meta-regression it was suggested that ethnicity might contribute little to the heterogeneity between the included studies. Through cumulative meta-analysis and sensitivity analysis it was supposed that the higher TNF-α levels of PCOS patients compared to healthy controls was stable and reliable. This meta-analysis suggests that the circulating TNF-α levels in women with PCOS are significantly higher than those in healthy controls. It may be involved in promoting insulin resistance and androgen excess of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.